Mirum Pharmaceuticals | 4:持股变动声明-高管 Vig Pamela
Mirum Pharmaceuticals | 4:持股变动声明-高管 Peetz Christopher
Mirum Pharmaceuticals | 4:持股变动声明-高管 BJERKHOLT ERIC
Mirum Pharmaceuticals | 10-Q:季度报表
Mirum Pharmaceuticals | 8-K:Mirum Pharmicals公布2024年第一季度财务业绩并提供业务最新情况
Mirum Pharmaceuticals | ARS:年度报告
Mirum Pharmaceuticals | DEFA14A:其他
Mirum Pharmaceuticals | DEF 14A:股东委托书决议
Mirum Pharmaceuticals | 4:持股变动声明-高管 BJERKHOLT ERIC
Mirum Pharmaceuticals | 4:持股变动声明-高管 Radovich Peter
Mirum Pharmaceuticals | 4:持股变动声明-高管 Radovich Peter
Mirum Pharmaceuticals | 4:持股变动声明-高管 Vig Pamela
Mirum Pharmaceuticals | 4:持股变动声明-高管 Longpre Lara
Mirum Pharmaceuticals | 4:持股变动声明-高管 Peetz Christopher
Mirum Pharmaceuticals | 4:持股变动声明-高管 BJERKHOLT ERIC
Mirum Pharmaceuticals | S-8:员工福利计划证券登记
Mirum Pharmaceuticals | 10-K:年度报表
Mirum Pharmaceuticals | NT 10-K:其他
Mirum Pharmaceuticals | 8-K:Mirum Pharmicals公布2023年第四季度和年终财务业绩并提供业务最新情况
Mirum Pharmaceuticals | SC 13G/A:超过5%持股股东披露文件(修正)-Eventide Asset Management, LLC(5.78%),Finny Kuruvilla, M.D. Ph. D.(5.78%)等
暂无数据